ChemoCentryx Inc. set a mid-range valuation among the would-be IPO class of 2012 when the autoimmune and cancer company announced a price range of $14.-$16. It hopes to sell 4 million shares through underwriters JPMorgan; Citi; and Cowen. A $15 price would raise $60 million and value the company at